HEM News Briefs

Study Shows High Polypharmacy in Older Patients With Hemophilia

Polypharmacy, defined as the use of 5 or more medications per day, has a high prevalence among patients with bleeding disorders such as hemophilia and von Willebrand disease (vWD), according to a recently published multicenter prospective observational study. Polypharmacy is a frequent problem for individuals older than 65 years. Due to the success of replacement…

CT scan of brain

New Algorithm Reduces CT Scans for Head Trauma in Pediatric Hemophilia

A research team has developed an adapted algorithm to help clinicians determine the need for computed tomography (CT) in pediatric patients with hemophilia who present at the emergency department with head trauma. The algorithm, published in Pediatric Blood & Cancer, is intended to reduce these patients’ exposure to unnecessary discomfort and radiation. “Management of hemophilia…

Blood sample

Outpatient Anticoagulation Management Services May Aid Hemophilia Treatment

Outpatient anticoagulation management services may play an important supportive role in the care of patients with hemophilia and other diseases, according to a commentary published in Research and Practice in Thrombosis and Haemostasis. The commentary was written by Bethany Samuelson Bannow, MD, from the Hemophilia Center at Oregon Health and Science University in Portland. When…

Artificial intelligence

Patient-Derived Tool Validates Hemarthrosis With Musculoskeletal Imaging

Patients with hemophilia often use a symptom-based algorithm to self-diagnose hemarthrosis to initiate timely and appropriate management. A new study published in Haemophilia validated these questionnaires by using objective point-of-care musculoskeletal ultrasound imaging modalities. This study evaluated a “painful episode questionnaire” which was developed by the Canadian Haemophilia Society as a tool to distinguish acute…

clinical trial research

Befovacimab May Not Be Safe for Patients With Hemophilia

Befovacimab treatment does not appear to be safe in patients with hemophilia despite favorable initial preclinical and clinical results, according to a new study published in Haemophilia.  This is based on the results of a multiple-dose, dose-escalating phase 2 clinical trial that had to be terminated early due to thrombosis.  During the trial, 24 patients…

blood and serum

Increased DNA Methylation Linked With Unexplained Recurrent Hemophilia

Researchers reported that the methylation of DNA in the promoter region of the von Willebrand Factor (VWF) gene is linked to an increased risk of unexplained recurrent hemophilia, as published in Contrast Media & Molecular Imaging. Von Willebrand disease is caused by abnormally low levels of the clotting agent VWF, leading to various clinical manifestations of…

Factor VIIa-Released Extracellular Vesicles Contribute to Hemostatic Effect

Treatment with factor VIIa increases circulating extracellular vesicles from the endothelium in patients with hemophilia, according to a new study published in the Journal of Thrombosis and Haemostasis. The authors of the study also showed, using ex vivo experiments, that factor VIIa-released extracellular vesicles promote the activation of factor X. These findings raise the possibility…

plasma and antibodies

Plasma-Derived FVIII/VWF Protects Against Inhibitor Formation in Hemophilia

Researchers have discovered that plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) complex demonstrates greater protection against the formation of inhibitors than isolated FVIII in patients with hemophilia, as published in Haemophilia. One of the most severe complications of FVIII replacement therapy is the formation of neutralizing autoantibodies. Studies show that around 1 in 4 patients with…

injection

Efanesoctocog Alfa for Hemophilia Granted Breakthrough Therapy Designation

The experimental factor VIII therapy efanesoctocog alfa was granted Breakthrough Therapy Designation for the treatment of hemophilia A by the US Food and Drug Administration (FDA). This is the first time a factor VIII therapy has been awarded Breakthrough Therapy Designation by the FDA. The decision was based on results from a phase 3 clinical…

blood test tube

Baseline Factor Levels Inversely Correlate With Hemophilia Bleeding Rates

Researchers found that half of adolescents and adults with nonsevere hemophilia had experienced at least 1 bleed in the past, and that baseline factor (FVIII)/IX levels were inversely associated with the rate of joint bleeds, as published in Blood Advances. “In this international multicenter study among people with non‐severe hemophilia A and B the age…

Next post in HEM News Briefs